FDA approval of venetoclax (Venclexta) for newly-diagnosed acute myeloid leukaemia

Approval is in combination with azacitidine, or decitabine, or low-dose cytarabine in adults aged >75 years, or who have comorbidities that preclude use of intensive induction chemotherapy and is based on data from the Phase III VIALE-A and VIALE-C studies.

Source:

Biospace Inc.